Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Is there any data to use PIK3CA directed agents in mutated metastatic triple negative breast cancer?
Related Questions
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?
